Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Terapias biológicas anti‐factor de necrosis tumoral en el tratamiento del edema macular uveítico (EMU) para la uveítis no infecciosa

Información

DOI:
https://doi.org/10.1002/14651858.CD012577.pub2Copiar DOI
Base de datos:
  1. Cochrane Database of Systematic Reviews
Versión publicada:
  1. 18 diciembre 2018see what's new
Tipo:
  1. Intervention
Etapa:
  1. Review
Grupo Editorial Cochrane:

  1. Grupo Cochrane de Salud ocular y de la visión

Copyright:
  1. Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cifras del artículo

Altmetric:

Citado por:

Citado 0 veces por enlace Crossref Cited-by

Contraer

Autores

  • Robert J Barry

    Correspondencia a: Academic Unit of Ophthalmology, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK

    [email protected]

  • Mohammad O Tallouzi

    Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK

  • Nick Bucknall

    Shrewsbury, UK

  • Jonathan M Mathers

    Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK

  • Philip I Murray

    Academic Unit of Ophthalmology, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK

  • Melanie J Calvert

    Centre for Patient Reported Outcomes Research, Institute of Applied Health Research, University of Birmingham, Birmingham, UK

    NIHR Birmingham Biomedical Research Centre and NIHR Surgical Reconstruction and Microbiology Research Centre, University Hospitals Birmingham NHS Foundation Trust and University of Birmingham, Birmingham, UK

  • David J Moore

    Institute of Applied Health Research, University of Birmingham, Birmingham, UK

  • Alastair K Denniston

    Department of Ophthalmology, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

Contributions of authors

MT, AD, DM, RB and MC led the development of the protocol. AD, RB and PM provided clinical advice; DM and MC provided methodological advice. NB provided the patient‐public perspective. JM gave input in reviewing the protocol. RB and MT screened and reviewed all papers identified in the database search and drafted the review text. All review authors read and approved the final manuscript.

Sources of support

Internal sources

  • National Institute of Health Research (NIHR), UK.

    Melanie Calvert is funded by the NIHR Birmingham Biomedical Research Centre and the NIHR Surgical Reconstruction and Microbiology Research Centre at the University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

External sources

  • National Institute for Health Research (NIHR), UK.

    • This review represents an independent research project funded by the NIHR under the Clinical Doctoral Research Fellowship Scheme being undertaken at the University of Birmingham.

    • Richard Wormald, Co‐ordinating Editor for Cochrane Eyes and Vision (CEV) acknowledges financial support for his CEV research sessions from the Department of Health through the award made by the National Institute for Health Research to Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology for a Specialist Biomedical Research Centre for Ophthalmology.

    • This review was supported by the NIHR, via Cochrane Infrastructure funding to the CEV UK editorial base.

    The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, National Health Service (NHS) or the Department of Health.

Declarations of interest

RB: none known
MT: none known
NB: none known
JM: none known
PM: none known
MC reports receipt of personal fees from Astellas and Takeda and grants from the NIHR, Macmillan Cancer Support, HDRUK and Innovate UK outside the submitted work.
DM: none known
AD: none known

Acknowledgements

Cochrane Eyes and Vision (CEV) created and executed the electronic search strategies. We thank Anupa Shah, Managing Editor for CEV for help during the review process. We thank Peter Addison and Jennifer Evans for their comments on the protocol and review.

Version history

Published

Title

Stage

Authors

Version

2018 Dec 18

Anti‐tumour necrosis factor biological therapies for the treatment of uveitic macular oedema (UMO) for non‐infectious uveitis

Review

Robert J Barry, Mohammad O Tallouzi, Nick Bucknall, Jonathan M Mathers, Philip I Murray, Melanie J Calvert, David J Moore, Alastair K Denniston

https://doi.org/10.1002/14651858.CD012577.pub2

2017 Apr 11

Anti‐tumour necrosis factor biological therapies for the treatment of uveitic macular oedema (UMO) for non‐infectious uveitis

Protocol

Mohammad O Tallouzi, Robert J Barry, Nick Bucknall, Jonathan M Mathers, Philip I Murray, Melanie J Calvert, David J Moore, Alastair K Denniston

https://doi.org/10.1002/14651858.CD012577

Keywords

MeSH

Medical Subject Headings (MeSH) Keywords

Medical Subject Headings Check Words

Humans;

PICO

Population
Intervention
Comparison
Outcome

El uso y la enseñanza del modelo PICO están muy extendidos en el ámbito de la atención sanitaria basada en la evidencia para formular preguntas y estrategias de búsqueda y para caracterizar estudios o metanálisis clínicos. PICO son las siglas en inglés de cuatro posibles componentes de una pregunta de investigación: paciente, población o problema; intervención; comparación; desenlace (outcome).

Para saber más sobre el uso del modelo PICO, puede consultar el Manual Cochrane.

Study flow diagram
Figuras y tablas -
Figure 1

Study flow diagram

Ir a la figura de la revisiónAbrir en una pestaña nueva